ClinicalTrials.gg
CompletedNCT02267083Updated Jan 10, 2018Results posted

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

A Phase 2 interventional study of GPX-150 for Injection in Soft Tissue Sarcoma, sponsored by Gem Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-10.

Sponsored by Gem Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
536th of 800
22 · median 35
Started
2015
with 37 others
Phase 2
310 of 958
30 open now
Registered
501st of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 536th largest by enrollment of the 800 interventional ones that give a count, is one of 38 that started in 2015, is one of 310 in phase 2, and was the 501st registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.

Read the detailed description

This is an open-label, single arm study of GPX-150 in patients with soft tissue sarcoma. Approximately 22 patients will be treated in this study. The population for this study is adult patients with histologically proven advanced and/or metastatic malignant soft tissue sarcoma of intermediate or high histologic grade.

All patients who meet all entry criteria will receive GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity or subject withdrawal.

Prior to initiation of treatment, subjects will undergo screening and baseline evaluations. During all study visits, subjects will be evaluated for safety. The dose of GPX-150 may be reduced when subjects meet specified dose reduction safety criteria. Subjects will be evaluated regularly for safety and tolerability. Tumor measurements will be calculated at baseline (within 28 days prior to treatment initiation), then at regular intervals while receiving treatment for up to 1 year. After discontinuing the treatment phase of the study, safety assessments and tumor measurements will be performed 3 weeks after the last dose of study drug.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • soft tissue sarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Histological documentation of soft tissue sarcoma ( may be historical and may have been obtained from primary tumor or a site).
  3. Advanced and/or metastatic malignant soft tissue sarcoma of intermediate or high histologic grade. Excluded are the following sarcoma subtypes:

    • Well-differentiated liposarcoma or atypical lipomatous tumor
    • Embryonal or alveolar rhabdomyosarcoma
    • Ewing sarcoma of soft tissue or bone
    • Gastrointestinal stromal tumor (GIST)
    • Dermatofibrosarcoma protuberans
    • Alveolar soft part sarcoma
    • Solitary fibrous tumor
    • Clear cell sarcoma
    • Kaposi sarcoma
    • Extraskeletal myxoid chondrosarcoma
    • PEComa (perivascular epithelial cell tumor)
    • Myoepithelioma / mixed tumor
  4. as per 1.1.
  5. Subject has received either:

    • No prior chemotherapy for current sarcoma, or
    • A single course of gemcitabine and/or docetaxel as therapy that was completed at least 6 months prior to planned first dose
  6. Performance Status of 0 - 2.
  7. Adequate cardiac function:

    • above the institution's lower limit of normal
    • ≤ 450 msec for males or 470 msec for females.
  8. Willing and able to provide written .
  9. Male and female subjects must agree to use a highly reliable method of for the duration of the study.
  10. Women of must have a serum pregnancy test performed within 28 days prior to the first day of study drug dosing.

Exclusion criteria

Exclusion Criteria:

  1. Sarcomas arising from bone or cartilage, e.g. chondrosarcoma, osteosarcoma, chordoma.
  2. Subject is eligible for a potentially curative therapy.
  3. Prior primary chemotherapy.
  4. Prior radiotherapy to > 25% of bone marrow volume.
  5. Treatment within 28 days prior to Dose 1 with:

    • Palliative surgery or radiotherapy.
    • Approved anticancer therapy including chemotherapy or immunotherapy.
    • treatments noted in the product labelling for doxorubicin, including trastuzumab and inhibitors and inducers of , CYP2D6, or P-gp.
    • An therapy.
    • Any major surgery (e.g. requiring general anesthesia).
  6. Inadequate bone marrow, liver, and renal function, as assessed by the following laboratory parameters:

    1. (ANC) \< 1,500/mm3.
    2. count \< 100,000/mm3.
    3. Total > 1.5× (upper limit of normal).
    4. and AST > 2.5×ULN. For patients with documented liver , ALT and AST > 5×ULN.
    5. Serum creatinine > 1.5 x ULN.
    6. (INR) and activated partial thromboplastin time [PTT] ≥ 1.5×ULN, if not therapeutically anticoagulated.
    7. Serum albumin \< 3.0 gm/dL.
  7. Congestive heart failure > Class II Functional Classification, current pericarditis, myocardial infarction within 6 months, or symptomatic coronary artery disease.
  8. Unstable or concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol.
  9. Active infection requiring systemic antibacterial/antibiotic, antifungal, or antiviral therapy.
  10. Documented metastases to brain or meninges.
  11. Any other than soft tissue sarcoma within the last 5 years prior to screening, with the exception of cervical carcinoma in situ, basal cell carcinoma, or superficial bladder tumors that have been successfully and curatively treated with no evidence of recurrent or residual disease.
  12. Body surface area (BSA) ≥ 2.4 m2.
  13. Currently pregnant or nursing.
  14. Known allergy to any of the study drugs or their .
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    GPX-150

    GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.

    Drug: GPX-150 for Injection

Interventions

  • DrugCamsirubicinStudies of CamsirubicinCamsirubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.

    Also known as: GPX-150, 5-imino-13-deoxy-doxorubicin HCl

06

What researchers measure

Primary outcomes

  1. Number of Subjects Progression-free at 12 Months Per RECIST 1.1

    The primary efficacy endpoint is the number of patients who were progression-free at 12 months, which is obtained by inversion of the Kaplan-Meier curve for progression-free survival (PFS) at 12 months. Of note, the statistical comparison to historical sarcoma data described in the protocol was not performed due to an enrollment of less than the planned sample size of 30 subjects. Progression is defined using RECIST 1.1, as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: 12 months from the beginning of study treatment

Secondary outcomes

  1. Number of Subjects Progression-free at Six Months Per RECIST 1.1

    This secondary efficacy endpoint is the progression-free rate (PFR) at 6 months, obtained from the Kaplan-Meier curve for progression-free survival (PFS).

    Time frame: 6 months from the beginning of the study treatment

  2. Number of Subjects Experiencing Adverse Events

    Subjects who received at least one dose were included in safety analyses. Adverse events were tabulated by System Organ Class (SOC) and Preferred Term (PT) and coded using MedDRA Version 19.1. Safety and tolerability was determined by frequency, nature, and severity of adverse events and the profile of toxicities.

    Time frame: From the beginning of study treatment and up to 12 months

Other outcomes

  1. Number of Subjects With Tumor Response Per RECIST 1.1

    Tumor assessments using contrast enhanced computerized tomography (CT) scan of the Chest/Abdomen/Pelvis were performed to assess overall tumor burden. Response rate (RR), where response is defined as complete response (CR), partial response (PR), or stable disease (SD). Determination of CR or PR requires confirmation at the time of the next tumor assessment. An outcome of SD requires at least one assessment 6 weeks after the initiation of dosing. Progression is defined using RECIST 1.1, as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: Assessed during screening, then every 6 weeks for the first 24 weeks on study, and then every 9 weeks for the next 24 weeks for up to 1 year. Subjects will be in the study for up to 1 year, or until disease progression or unacceptable toxicity.

07

Results

Posted Jan 10, 2018

Participant flow

Participant flow — Overall Study
MilestoneGPX-150
Started22
Completed3
Not completed19

Outcome measures

PrimaryNumber of Subjects Progression-free at 12 Months Per RECIST 1.1

The primary efficacy endpoint is the number of patients who were progression-free at 12 months, which is obtained by inversion of the Kaplan-Meier curve for progression-free survival (PFS) at 12 months. Of note, the statistical comparison to historical sarcoma data described in the protocol was not performed due to an enrollment of less than the planned sample size of 30 subjects. Progression is defined using RECIST 1.1, as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
12 months from the beginning of study treatment
Reported as:
Count of participants · Participants
Number of Subjects Progression-free at 12 Months Per RECIST 1.1
ParticipantsGPX-150
Number of Subjects Progression-free at 12 Months Per RECIST 1.13
SecondaryNumber of Subjects Progression-free at Six Months Per RECIST 1.1

This secondary efficacy endpoint is the progression-free rate (PFR) at 6 months, obtained from the Kaplan-Meier curve for progression-free survival (PFS).

Time frame:
6 months from the beginning of the study treatment
Reported as:
Count of participants · Participants
Number of Subjects Progression-free at Six Months Per RECIST 1.1
ParticipantsGPX-150
Number of Subjects Progression-free at Six Months Per RECIST 1.18
SecondaryNumber of Subjects Experiencing Adverse Events

Subjects who received at least one dose were included in safety analyses. Adverse events were tabulated by System Organ Class (SOC) and Preferred Term (PT) and coded using MedDRA Version 19.1. Safety and tolerability was determined by frequency, nature, and severity of adverse events and the profile of toxicities.

Time frame:
From the beginning of study treatment and up to 12 months
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Adverse Events
ParticipantsGPX-150
Number of Subjects Experiencing Adverse Events22
Other pre-specifiedNumber of Subjects With Tumor Response Per RECIST 1.1

Tumor assessments using contrast enhanced computerized tomography (CT) scan of the Chest/Abdomen/Pelvis were performed to assess overall tumor burden. Response rate (RR), where response is defined as complete response (CR), partial response (PR), or stable disease (SD). Determination of CR or PR requires confirmation at the time of the next tumor assessment. An outcome of SD requires at least one assessment 6 weeks after the initiation of dosing. Progression is defined using RECIST 1.1, as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
Assessed during screening, then every 6 weeks for the first 24 weeks on study, and then every 9 weeks for the next 24 weeks for up to 1 year. Subjects will be in the study for up to 1 year, or until disease progression or unacceptable toxicity.
Reported as:
Count of participants · Participants
Number of Subjects With Tumor Response Per RECIST 1.1
ParticipantsGPX-150
PD at final turmor assessment14
SD at final tumor assessment5
CR at final tumor assessment0
PR at final tumor assessment0

Adverse events

Collected over 1 year, 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GPX-1502/22 (9.1%)22/22 (100%)22/22 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventGPX-150
VomitingGastrointestinal disorders2/22
Febrile neutropeniaBlood and lymphatic system disorders1/22
AnaemiaBlood and lymphatic system disorders1/22
Myocardial infarctionCardiac disorders1/22
Abdominal painGastrointestinal disorders1/22
DiarrhoeaGastrointestinal disorders1/22
IleusGastrointestinal disorders1/22
NauseaGastrointestinal disorders1/22
Small intestine obstructionGastrointestinal disorders1/22
Cholecystitis chronicHepatobiliary disorders1/22
Most frequent other events
Showing 10 of 33
Most frequent other events
EventGPX-150
NauseaGastrointestinal disorders13/22
FatigueGeneral disorders11/22
ConstipationGastrointestinal disorders10/22
VomitingGastrointestinal disorders10/22
Abdominal painGastrointestinal disorders7/22
Back painMusculoskeletal and connective tissue disorders6/22
Pain in extremityMusculoskeletal and connective tissue disorders6/22
AnemiaBlood and lymphatic system disorders5/22
Injection fraction decreasedInvestigations5/22
Anorexia nervosaMetabolism and nutrition disorders5/22

Baseline characteristics

The Safety Population consists of all subjects who received at least 1 dose of GPX-150 and the Intent-to-Treat (ITT) Population consists of all subjects in the Safety Population who had at least one tumor assessment using RECIST 1.1 or who died prior to any tumor assessment.

Age, Continuous
Age, Continuous(years)GPX-150
Mean59.4 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)GPX-150
Female7
Male15
Region of Enrollment
Region of Enrollment(participants)GPX-150
United States22
08

Study locations

4 sites
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Nov 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Oct 17, 2014
Start
Jan 7, 2015
Primary completionActual
Nov 11, 2015
CompletionActual
Aug 18, 2016
Results first posted
Jan 10, 2018
Last update
Jan 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02267083
Lead sponsor
Gem Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 17, 2014
Start date
Jan 7, 2015
Primary completion
Nov 11, 2015
Completion
Aug 18, 2016
Results posted
Jan 10, 2018
Last update
Jan 10, 2018

Study contacts

Mohammed Milhem, MD
principal investigator · University of Iowa Holden Comprehensive Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camsirubicin

Start the discussion